We Offer Worldwide Shipping
Login Wishlist

Saikosaponin C

$113

  • Brand : BIOFRON

  • Catalogue Number : BF-S2015

  • Specification : 98%

  • CAS number : 20736-08-7

  • Formula : C48H78O17

  • Molecular Weight : 927.12

  • PUBCHEM ID : 167927

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-S2015

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

927.12

Appearance

White crystalline powder

Botanical Source

root of Bupleurum chinense DC.

Structure Type

Terpenoids

Category

Standards;Natural Pytochemical;API

SMILES

Synonyms

Saikosaponin c standard/(3β,16β)-16,23-dihydroxy-13,28-epoxyolean-11-en-3-yl 6-deoxy-α-L-altropyranosyl-(1->4)-[β-D-glucopyranosyl-(1->6)]-β-D-glucopyranoside/SaikosaponinC/β-D-glucopyranoside, (3β,16β)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl O-6-deoxy-α-L-altropyranosyl-(1->4)-O-[β-D-glucopyranosyl-(1->6)]-/Saikosaponin C/SAIKOSAPONIN A(P)/Saikosaponian C/β-D-Glucopyranoside, (3β,16β)-13,28-epoxy-16,23-dihydroxyolean-11-en-3-yl O-6-deoxy-β-L-altropyranosyl-(1->4)-O-[β-D-glucopyranosyl-(1->6)]-/chikusakoside II/SAIKOSAPONIN C(P)/6)]-)/(3β,16β)-16,23-Dihydroxy-13,28-epoxyolean-11-en-3-yl 6-deoxy-β-L-altropyranosyl-(1->4)-[β-D-glucopyranosyl-(1->6)]-β-D-glucopyranoside

IUPAC Name

Density

1.4±0.1 g/cm3

Solubility

Methanol

Flash Point

Boiling Point

Melting Point

310-314ºC

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2932900000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:20736-08-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

26710244

Abstract

Alzheimer’s disease (AD) is a chronic neurodegenerative disease and the risk of developing it increases with advancing age. In this study, we investigated the protective effects of saikosaponin C (SSc), one of the main bioactive components produced by the traditional Chinese herb, radix bupleuri, the root of Bupleurum falcatum, against AD in various neuronal models. Interestingly, we found that SSc has dual effects on AD by targeting amyloid beta (Aβ) and tau, two key proteins in AD. SSc significantly suppressed the release of both Aβ peptides 1-40 and 1-42 into cell culture supernatants, though it does not affect BACE1 activity and expression. SSc also inhibited abnormal tau phosphorylation at multiple AD-related residues. Moreover, SSc seems to have beneficial effects on cellular tau function; it accelerated nerve growth factor-mediated neurite outgrowth and increased the assembly of microtubules. In addition, SSc increased synaptic marker proteins such as synaptophysin and PSD-95. Considering its various biological activities, our results suggest that SSc might be a novel therapeutic tool for treating human AD and other neurodegenerative diseases. Tau and amyloid beta are two key features in Alzheimer’s disease. Saikosaponin C, an active component of Bupleuri Radix, inhibits abnormal tau phosphorylation and amyloid beta production, thereby promoting synaptic integrity. Saikosaponin C also prevents amyloid beta-induced apoptosis in brain vascular endothelial cells. Therefore, Saikosaponin C may provide a new therapeutic strategy for treatment of neurodegenerative diseases, including Alzheimer’s disease.

KEYWORDS

Alzheimer's disease; amyloid beta; neurodegenerative diseases; saikosaponin C; tau; therapeutic tool.

Title

A Potential Therapeutic Effect of Saikosaponin C as a Novel Dual-Target anti-Alzheimer Agent

Author

Tae Ho Lee 1 , Sungha Park 2 , Mi-Hyeon You 1 , Ji-Hong Lim 3 , Sang-Hyun Min 4 , Byeong Mo Kim 2

Publish date

2016 Mar

PMID

31531682

Abstract

Objective: Saikosaponin c (SSc), a compound purified from the traditional Chinese herb of Radix Bupleuri was previously identified to exhibit anti-HBV replication activity. However, the mechanism through which SSc acts against HBV remains unknown. In this study, we investigated the mechanism of SSc mediated anti-HBV activity.
Methods: HepG2.2.15 cells were cultured at 37 ℃ in the presence of 1-40 μg/mL of SSc or DMSO as a control. The expression profile of HBV markers, cytokines, HNF1α and HNF4α were investigated by real-time quantitative PCR, Elisa, Western blot and Dot blotting. Knockdown of HNF1α or HNF4α in HepG2.2.15 cells was mediated by two small siRNAs specifically targeting HNF1α or HNF4α.
Results: We found that SSc stimulates IL-6 expression, leading to attenuated HNF1α and HNF4α expression, which further mediates suppression of HBV pgRNA synthesis. Knockdown of HNF1α or HNF4α in HepG2.2.15 cells by RNA interference abrogates SSc’s anti-HBV role. Moreover, SSc is effective to both wild-type and drug-resistant HBV mutants.
Conclusion: SSc inhibits pgRNA synthesis by targeting HNF1α and HNF4α. These results indicate that SSc acts as a promising compound for modulating pgRNA transcription in the therapeutic strategies against HBV infection.

KEYWORDS

Alzheimer's disease; amyloid beta; neurodegenerative diseases; saikosaponin C; tau; therapeutic tool.

Title

Saikosaponin C Exerts anti-HBV Effects by Attenuating HNF1α and HNF4α Expression to Suppress HBV pgRNA Synthesis

Author

Yanchao Pan 1 , Zhiyi Ke 2 , Hong Ye 3 , Lina Sun 2 , Xiaoyan Ding 2 , Yun Shen 2 , Runze Zhang 2 , Jing Yuan 4

Publish date

2019 Dec

PMID

26828474

Abstract

Saikosaponin C (SSC) is one of the major active constituents of dried Radix bupleuri root (Chaihu in Chinese) that has been widely used in China to treat a variety of conditions, such as liver disease, for many centuries. The binding of SSC to human serum albumin (HSA) was explored by fluorescence, circular dichroism (CD), UV-vis spectrophotometry, and molecular docking to understand both the pharmacology and the basis of the clinical use of SSC/Chaihu. SSC produced a concentration-dependent quenching effect on the intrinsic fluorescence of HSA, accompanied by a blue shift in the fluorescence spectra. The Stern-Volmer equation showed that this quenching was dominated by static quenching. The binding constant of SSC with HSA was 3.72 × 10³ and 2.99 × 10³ L·mol(-1) at 26 °C and 36 °C, respectively, with a single binding site on each SSC and HSA molecule. Site competitive experiments demonstrated that SSC bound to site I (subdomain IIA) and site II (subdomain IIIA) in HSA. Analysis of thermodynamic parameters indicated that hydrogen bonding and van der Waals forces were mostly responsible for SSC-HSA association. The energy transfer efficiency and binding distance between SSC and HSA was calculated to be 0.23 J and 2.61 nm at 26 °C, respectively. Synchronous fluorescence and CD measurements indicated that SSC affected HSA conformation in the SSC-HSA complex. Molecular docking supported the experimental findings in conformational changes, binding sites and binding forces, and revealed binding of SSC at the interface between subdomains IIA-IIB.

KEYWORDS

Chaihu; Radix bupleuri; human serum albumin; molecular docking; saikosaponin C; static quenching.

Title

Binding Between Saikosaponin C and Human Serum Albumin by Fluorescence Spectroscopy and Molecular Docking

Author

Yi-Cun Chen 1 2 , Hong-Mei Wang 3 , Qing-Xia Niu 4 , Dan-Yan Ye 5 , Guo-Wu Liang 6

Publish date

2016 Jan 28


Description :

Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression[1].